Therapeutic Drug Monitoring / mAb-based Biosimilars ELISA
KRIBIOLISA KRISHGEN BIOSYSTEMS offers Pharmacokinetics (PK) ELISA Kits for the quantification of serum and plasma protein drug levels to provide accurate pharmacokinetic (PK) data that will help optimize drug dosing regimens. These mAb-based ELISA are developed for use with biosimilars and biologics.
Our range of assays is currently the largest range of biosimilars ELISA in the world, with over 350 mAb drug targets covered for quantitative detection. Whether it’s development of biosimilar drugs or generics for monoclonal antibody drugs for cancer immunotherapy (Trastuzumab ELISA, Pertuzumab ELISA, Bevacizumab ELISA, Alemtuzumab ELISA etc), for auto-immune diseases like Crohn’s disease, multiple sclerosis, or rheumatoid arthritis (Infliximab ELISA, Natalizumab ELISA, Golimumab ELISA), or even for for ailments like osteoporosis or psoriasis (Ustekinumab ELISA, Denosumab ELISA), we have the right Therapeutic Drug Monitoring ELISA and Anti-Drug Antibody ELISA for you.
Several products are available with CE certification for clinical use, with others in the process of being approved. Please look for the “Regulatory Status” when choosing the assay (RUO or CE).
Featured Products
- All validation, verification and lot releases for these ELISA are performed according to best-in-class scientific guidelines – including a stringent seven-point validation to ensure quality and robustness lot-over-lot.
- Where available, validation of the kit against international standards from NIBSC / WHO
Learn more about our NIBSC validation on our blog here.
- These ELISA employ anti-idiotypic monoclonal antibodies in a sandwich assay format, ensuring exceptional specificity and sensitivity in drug detection, even at low concentrations.
- Calibrated against innovator drugs to ensure a high degree of accuracy
- To ensure no matrix interference and reproducible dilutional linearity, we run several serum and plasma spiking experiments at various dilutions to optimize. Inter and intra assay CV in accordance with FDA & EMEA requirements CV <10%.
Pool Intra Assay %CV Inter Assay %CV Low <10% <10% Medium <5% <5% High <5% <5%
- Validated against ICH / EMA guidelines under the ISO 13485 certification.
- 96 well plates with break apart strips includes lyophilized standards for stability.
- Expiry period of a minimum 10 months
- Ship at ambient temperature, with lyophilized / stabilized reagents
Performance Characteristics and Validation Information:
Sensitivity: The limit of detection is defined as the lowest detectable concentration corresponding to a signal of Mean of ‘0’ standard plus 2* SD. Each kit mentions sensitivity in the datasheet.
Calibration: Several KRIBIOLISA kits have been Calibrated against International Standards from the National Institute of Biologicals and Control (NIBSC), Potters Bar, Hertfordshire EN6 3QG, UK.
The Standards provided in the kit are also calibrated against commercially sourced drugs and alternate recombinant biosimilars.
Recovery and Matrix Effect:
Precision: Precision is defined as the percent coefficient of variation (%CV) i.e. standard deviation divided by the mean and multiplied by 100. Assay precision was determined by both intra and inter assay reproducibility on two pools with low, medium, and high concentrations. While actual precision may vary from laboratory to laboratory and technician to technician, it is recommended that all operators achieve precision below these design goals before reporting results.
360+ Pharmacokinetic (PK) ELISA
Krishgen manufactures the world’s largest range of ELISA for biosimilars research and therapeutic drug monitoring. Need a custom assay range or want to run an animal sample? Speak to our team today!
